AZD-9291

AZD-9291

Catalog Number:
L002369816APE
Mfr. No.:
APE-B1104
Price:
$233
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          AZD-9291 is an irreversible inhibitor of mutant EGFR with IC50 values of 15nM, 17nM and 480nM, respectively for L858R/T790M, ex19del and wild-type EGFR [1].
          A series of mutations cause the resistance of EGFR, AZD-9291 is developed for an irreversible and selective inhibitor of the mutant EGFR. AZD-9291 binds to the ATP binding site of EGFR by targeting Cys 797. In EGFR recombinant enzyme assay, AZD-9291 shows about 200 times greater potency against the mutant EGFR than wild-type EGFR. AZD-9291 does not exhibit significant activity towards other receptor kinase. In vitro assays show that AZD-9291can inhibit EGFR phosphorylation with lower IC50 value in cell lines harboring sensitising EGFR mutants than in wild-type cell lines. Additionally, AZD9291 can induce profound shrinkage in mutant EGFR at low doses in xenograft models. This also happens in transgenic mouse tumor models. Mice treated with AZD9291 at the dose of 5 mg/kg/day display 80% reduction in tumor volume [1].

          [1] Darren A. E. Cross, Susan E Ashton, Serban Ghiorghiu, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery. 2014, June.

      • Properties
        • Alternative Name
          osimertinib
          CAS Number
          1421373-65-0
          Molecular Formula
          C28H33N7O2
          Molecular Weight
          499.61
          Purity
          99.81%
          Solubility
          ≥24.98 mg/mL in DMSO; insoluble in H2O; ≥8.09 mg/mL in EtOH with ultrasonic
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Hu X, Zhang ZY, et al. "A natural anthraquinone derivative shikonin synergizes with AZD9291 against wtEGFR NSCLC cells through reactive oxygen species-mediated endoplasmic reticulum stress." Phytomedicine. 2020;68:153189. PMID:32070867
          2. Richtmann S, Wilkens D, et al. "FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC." Cancers (Basel). 2019 May 11;11(5). pii: E652. PMID:31083571
          3. Cheriyan VT, Alsaab H, et al. "A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers." Oncotarget. 2018 Jul 3;9(51):29680-29697. PMID:30038713

    We Also Recommend

    N6022

    $312

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.